For the year ending 2025-12-31, CDXS had $32,054K increase in cash & cash equivalents over the period. -$23,847K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -43,974 |
| Depreciation and amortization | 5,248 |
| Reduction in the carrying amount of right-of-use assets | 3,044 |
| Stock-based compensation | 9,624 |
| Provision (recovery) for credit losses | -113 |
| Asset impairment and other charges | 0 |
| Impairment of investment in non-marketable securities | 300 |
| Equity securities earned from research and development activities | 0 |
| Non-cash interest expense | 1,305 |
| Amortization of discount on short-term investments | -1,234 |
| Other non-cash items | 6 |
| Financial assets | -8,507 |
| Inventories | 19 |
| Prepaid expenses and other assets | 1,694 |
| Accounts payable | -1,286 |
| Accrued compensation and other accrued liabilities | 2,848 |
| Other long-term liabilities | -3,161 |
| Deferred revenue | 6,919 |
| Net cash used in operating activities | -19,376 |
| Purchase of property and equipment | 4,471 |
| Proceeds from sale of property and equipment | 5 |
| Purchases of short-term investments | 57,158 |
| Proceeds from maturity of short-term investments | 85,126 |
| Proceeds from sale of short-term investments | 0 |
| Investment in non-marketable securities | 0 |
| Net cash provided by (used in) investing activities | 23,502 |
| Proceeds from exercises of stock options | 1,098 |
| Proceeds from issuance of stock under employee stock purchase plan | 505 |
| Proceeds from issuance of common stock in connection with equity sales agreements | 17,267 |
| Costs incurred in connection with equity sales agreements | 836 |
| Proceeds from long-term debt | 9,897 |
| Payment of debt issuance costs | 3 |
| Taxes paid related to net share settlement of equity awards | 0 |
| Net cash provided by financing activities | 27,928 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 32,054 |
| Cash, cash equivalents and restricted cash at the beginning of the year | 20,829 |
| Cash, cash equivalents and restricted cash at the end of the year | 52,883 |
CODEXIS, INC. (CDXS)
CODEXIS, INC. (CDXS)